# Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

> **NCT02283359** · PHASE1 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 3 (actual)

## Conditions studied

- Esophageal Cancer
- Gastric Cancer

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT02283359
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2015-12
- **Final completion:** 2016-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Principal Investigator left the institution
- **Last updated:** 2016-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02283359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02283359, "Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02283359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*